PharmTech Drug Digest 11.20
|Articles|January 23, 2014

Shire Appoints Susan Kilsby as Its New Chairman Effective April 2014

Author(s)Melanie Sena

Shire appoints Susan Kilsby as its New Chairman.

Shire has reported that Matthew Emmens will retire as non-executive chairman and Susan Kilsby, chairman of Shire’s Audit, Compliance & Risk Committee, will succeed him after the conclusion of Shire’s AGM on April 29, 2014. Emmens joined the company as chief executive in 2003 and became chairman of Shire in 2008. Kilsby joined the Shire Board as a non-executive director in September 2011. In May 2013, she was appointed chairman of Shire’s Audit, Compliance & Risk Committee. Dominic Blakemore will replace Kilsby’s position as chairman of Shire’s Audit, Compliance & Risk Committee. In addition, Kilsby’s will become a member of Shire’s Nomination Committee, effective February 1, 2014.

Source: Shire


Related to this article

Are Your Supplier Selection and Oversight Processes Robust Enough?
Despite best efforts to ensure a contract organization is following GMPs, a warning letter is issued by the FDA. Susan J. Schniepp, distinguished fellow at Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical at Parexel, provide advice for create a robust supplier selection and oversight system.
white pill capsule isolated on white background | Image Credit: ©F16-ISO100 -stock.adobe.com
PharmTech spoke with Chiara Bergerone, deputy CEO of Roquette’s Health & Pharma Solutions Business, about the company’s hydroxypropyl methylcellulose (HPMC) capsule, which was previewed at CPHI Milan 2026 in October.
Transitioning mRNA from R&D to GMP
Marco Pupo, PhD, innovation and development coordinator at Anemocyte, discusses the R&D-to-GMP transition and the changing shape of mRNA manufacturing facilities.